Immunogenicity and Safety of Measles-Mumps-Rubella, Varicella and Haemophilus influenzae Type b Vaccines Administered Concurrently With a Fourth Dose of Heptavalent Pneumococcal Conjugate Vaccine Compared With the Vaccines Administered Without Heptavalent Pneumococcal Conjugate Vaccine

2006 ◽  
Vol 25 (4) ◽  
pp. 306-311 ◽  
Author(s):  
Steven B. Black ◽  
Carolyn O. Cimino ◽  
John Hansen ◽  
Edwin Lewis ◽  
Paula Ray ◽  
...  
Keyword(s):  
Haemophilus Influenzae ◽  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Haemophilus Influenzae Type ◽  
Haemophilus Influenzae Type B ◽  
Type B ◽  
Fourth Dose ◽  
Heptavalent Pneumococcal Conjugate Vaccine

Pneumonia Prevention during a Humanitarian Emergency: Cost-effectiveness of Haemophilus Influenzae Type B Conjugate Vaccine and Pneumococcal Conjugate Vaccine in Somalia

2015 ◽  
Vol 30 (4) ◽  
pp. 402-411 ◽  
Author(s):  
Lisa M. Gargano ◽  
Rana Hajjeh ◽  
Susan T. Cookson
Keyword(s):  
Cost Effectiveness ◽  
Haemophilus Influenzae ◽  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Disease Burden ◽  
Cost Effective ◽  
Haemophilus Influenzae Type ◽  
Haemophilus Influenzae Type B ◽  
Type B ◽  
Humanitarian Emergency

AbstractBackgroundPneumonia is a leading cause of death among children less than five years old during humanitarian emergencies. Haemophilus influenzae type b (Hib) and Streptococcus pneumoniae are the leading causes of bacterial pneumonia. Vaccines for both of these pathogens are available to prevent pneumonia.ProblemThis study describes an economic analysis from a publicly funded health care system perspective performed on a birth cohort in Somalia, a country that has experienced a protracted humanitarian emergency.MethodsAn impact and cost-effectiveness analysis was performed comparing: no vaccine, Hib vaccine only, pneumococcal conjugate vaccine 10 (PCV10) only, and both together administered through supplemental immunization activities (SIAs). The main summary measure was the incremental cost per disability-adjusted life-years (DALYs) averted. One-way sensitivity analysis was conducted for uncertainty in parameter values.ResultsEach SIA would avert a substantial number of cases and deaths. Compared with no vaccine, the DALYs averted by two SIAs for two doses of Hib vaccine was US $202.93 (lower and upper limits: $121.80-$623.52), two doses of PCV10 was US $161.51 ($107.24-$227.21), and two doses of both vaccines was US $152.42 ($101.20-$214.42). Variables that influenced the cost-effectiveness for each strategy most substantially were vaccine effectiveness, case fatality rates (CFRs), and disease burden.ConclusionsThe World Health Organization (WHO) defines a cost-effective intervention as costing one to three times the per capita gross domestic product (GDP; in 2011, for Somalia=US $112). Based on the presented model, Hib vaccine alone, PCV10 alone, or Hib vaccine and PCV10 given together in SIAs are cost-effective interventions in Somalia. The WHO/Strategic Advisory Group of Experts decision-making factors for vaccine deployment appear to have all been met: the disease burden is large, the vaccine-related risk is low, prevention in this setting is more feasible than treatment, the vaccine duration probably is sufficient for the vulnerable period of the child’s life, cost is reasonable, and herd immunity is possible.GarganoLM, HajjehR, CooksonST. Pneumonia prevention during a humanitarian emergency: cost-effectiveness of Haemophilus influenzae type b conjugate vaccine and pneumococcal conjugate vaccine in Somalia. Prehosp Disaster Med. 2015;30(4):110.

Sign in / Sign up

Export Citation Format

Share Document